Atezolizumab did not confer any benefits when added to SBRT in a phase 3 trial of patients with inoperable, early-stage NSCLC.

Phase 2 trial results support Isa-KRd as a standard treatment option for patients with high-risk, newly diagnosed multiple myeloma, according to researchers.

Children with non-germinomatous germ cell tumors may have better IQ recovery if they receive proton radiotherapy rather than photon radiotherapy.

Medical school attrition rates are higher among lesbian, gay, and bisexual (LGB) medical students than among their non-LGB peers.

A new SARS-CoV-2 variant, NB.1.8.1, may now account for more than one-third of all COVID-19 cases in the US, health officials say.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources.

Omitting pelvic lymphadenectomy may be beneficial for patients with early-stage cervical cancer undergoing sentinel lymph node biopsy and radical hysterectomy.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

(HealthDay News) — More than 460 employees who were laid off from their jobs at the US Centers for Disease Control and Prevention (CDC) are being rehired, the Associated Press reported last week.

(HealthDay News) — Circulating tumor DNA (ctDNA) can be detected more than 3 years prior to a clinical cancer diagnosis, according to a research brief published in Cancer Discovery.